These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 23752109

  • 21. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B, Jeong JH, Anderson S, Wolmark N.
    J Natl Cancer Inst; 2004 Dec 15; 96(24):1823-31. PubMed ID: 15601638
    [Abstract] [Full Text] [Related]

  • 22. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
    Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F.
    Curr Opin Obstet Gynecol; 2007 Feb 15; 19(1):56-62. PubMed ID: 17218853
    [Abstract] [Full Text] [Related]

  • 23. Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
    Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, Yazilitas D, Bal O, Kucukoner M, Yildirim Ozdemir N, Demirci U, Gunaydin Y, Yildiz R, Karaca H, Umit Unal O, Gumus M, Benekli M, Buyukberber S.
    Onkologie; 2013 Feb 15; 36(10):554-8. PubMed ID: 24107908
    [Abstract] [Full Text] [Related]

  • 24. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA.
    J Clin Oncol; 2013 Mar 20; 31(9):1157-63. PubMed ID: 23382472
    [Abstract] [Full Text] [Related]

  • 25. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F, Redana S, Viale G, Sanna G, Donadio M, Valabrega G, del Curto B, Bottini A, Botti G, dei Tos AP, Jacomuzzi ME, Di Bonito M, Danese S, Clavarezza M, Kulka J, Di Palma S, Durando A, Sapino A, Aglietta M.
    Clin Breast Cancer; 2008 Oct 20; 8(5):436-42. PubMed ID: 18952558
    [Abstract] [Full Text] [Related]

  • 26. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
    Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ.
    J Clin Oncol; 2010 Jul 20; 28(21):3422-8. PubMed ID: 20530280
    [Abstract] [Full Text] [Related]

  • 27. Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study.
    Guiu S, Arnould L, Bonnetain F, Dalban C, Favier L, Desmoulins I, Créhange G, Coutant C, Fumoleau P, Coudert B.
    Breast; 2013 Jun 20; 22(3):301-8. PubMed ID: 22863283
    [Abstract] [Full Text] [Related]

  • 28. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A, Smith I.
    Breast; 2011 Oct 20; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [Abstract] [Full Text] [Related]

  • 29. Real-world outcomes of different treatments in the management of patients with HER-2 positive breast cancer: a retrospective study.
    Chitapanarux I, Trakultivakorn H, Srisukho S, Somwangprasert A, Watcharachan K, Srikawin J, Chaiwun B, Traisathit P.
    J Med Assoc Thai; 2013 Jun 20; 96(6):709-15. PubMed ID: 23951829
    [Abstract] [Full Text] [Related]

  • 30. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.
    J Clin Oncol; 2003 Aug 01; 21(15):2889-95. PubMed ID: 12885806
    [Abstract] [Full Text] [Related]

  • 31. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
    O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD.
    J Clin Oncol; 2015 Aug 20; 33(24):2600-8. PubMed ID: 26101239
    [Abstract] [Full Text] [Related]

  • 32. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01.
    Sacco M, Valentini M, Belfiglio M, Pellegrini F, De Berardis G, Franciosi M, Nicolucci A, Italian Interdisciplinary Group for Cancer Care Evaluation.
    J Clin Oncol; 2003 Jun 15; 21(12):2276-81. PubMed ID: 12805326
    [Abstract] [Full Text] [Related]

  • 33. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
    Fagnani F, Colin X, Arveux P, Coudert B, Misset JL.
    Bull Cancer; 2007 Jul 04; 94(7):711-20. PubMed ID: 17723955
    [Abstract] [Full Text] [Related]

  • 36. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
    Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F.
    J Clin Oncol; 2009 Dec 20; 27(36):6129-34. PubMed ID: 19917839
    [Abstract] [Full Text] [Related]

  • 37. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S, Pilgrim H, Hind D.
    Health Technol Assess; 2009 Jun 20; 13 Suppl 1():1-6. PubMed ID: 19567207
    [Abstract] [Full Text] [Related]

  • 38. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
    Jahanzeb M.
    Clin Breast Cancer; 2008 Aug 20; 8(4):324-33. PubMed ID: 18757259
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM.
    J Clin Oncol; 2007 Feb 20; 25(6):634-41. PubMed ID: 17308268
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.